Entrepreneurs are, by definition, ideas people and typically not very good at the detail & not very good completer/finishers. This puts them in the precarious position of getting bored if they don't get immediate results, and this can easily lead them to chase the next shiny new object! In today's podcast, I dig into this issue and share 7 strategies to get focused and avoid being distracted by shiny new objects. Time Stamp [01:29] A definition of Shiny New Object Syndrome [02:00] What triggers Shiny New Object Syndrome? [02:03] Information overload and FOMO [03:40] 4 drawbacks of following shiny new objects [05:38] 7 strategies to help you stay focused and avoid shiny new objects [05:53] Strategy 1: Have a plan, stick to it and revisit it regularly [06:12] Strategy 2: Translate your plan into months, weeks and days [06:26] Strategy 3: Use your plan to assess new ideas against - great idea or shiny new object? [07:13] Strategy 4: Write new ideas down to get them out of your head [07:30] Strategy 5: Limit the number of projects you focus on [07:58] Strategy 6: Limit the number of people, blogs or podcasts you listen to and get influenced by [08:18] Strategy 7: Limit the amount of time you spend on social media and the channels you follow [09:06] What is Monkey Mind and do you suffer from it? [10:11] The consequences of having a Monkey Mind! [11:10] 3 tips to calm your Monkey Mind [11:23] Tip 1: Know that it is possible to manage your Monkey Mind [11:49] Tip 2: Have a conversation with your Monkey Mind [12:05] Tip 3: Keep a journal Quotations “A strategy you currently implement might not be sexy but don't let shiny new objects distract you from it if it works” - Rob Da Costa “Get ideas out of your head by writing them down on paper. This means you won't forget them but you can let them go and focus on the task at hand” - Rob Da Costa Rate, Review, & Subscribe on Apple Podcasts “I enjoy listening to The Agency Accelerator Podcast. I always learn something from every episode.” If that sounds like you, please consider rating and reviewing my show! This helps me support more people — just like you — move towards a Self-Running Agency. Scroll to the bottom, tap to rate with five stars, and select “Write a Review.” Then be sure to let me know what you loved most about the episode! Also, if you haven't done so already, subscribe to the podcast. I'm adding a bunch of bonus episodes to the feed and, if you're not subscribed, there's a good chance you'll miss out. Subscribe now! Useful links mentioned in this episode: FREE Workshop: 3 Ways to Raise Your Prices & ProfitsMindset GuideProductivity Guide
Feeling overwhelmed today? Way too many things on your to-do list? Get in line, right? Wondering what you'll fix for dinner? I have an idea for you: sheet pan dinners that take 30 minutes or less. They're quick, easy and satisfying. And I have a freebie with 4 recipes for you too. Just what you need to make your day a little bit easier.Visit Procarenow.com for all of your vitamin, calcium and protein needs. Use Code: Susan10 to save 10%Link to my interview with Dr. Connie Stapleton on her BariAfterCare podcast Audio podcasthttps://www.youtube.com/watch?v=FDS7A0d2NeI Video versionSheet Pan DinnersA sheet pan dinner is when the majority of dinner is prepared on one pan…a sheet pan.You might be thinking. Why sheet pan dinners. Don't knock it till you try it. There are lots of benefits to sheet pan dinners. Let's talk about four in today's episode plus I'll share my go-to sheet pan recipe for you to try.Get your FREEBIE: 4 sheet pan recipesJoin me in the Facebook private groupFollow on Apple Podcasts:"I love Dr. Susan and Bariatric Surgery Success." If this sounds like you, would you please rate and review my podcast? Click here. Then click on "Listen to Apple Podcasts" at the top. Scroll down to where you see Ratings & Reviews and tap on "Write a Review". Yes, I'd love a 5 star review! LOL Be sure and let me know what you love most about the podcast. Thank you for your time! If you haven't followed the podcast, be sure to Follow/Subscribe now so you never miss an episode.
This behind the scenes clip is a response to a question I received from one of my students around how to be okay stepping out of the "box" everyone else seems to be totally comfortable fitting themselves into. And when we do? How to talk about what we do outside of nutrition so that people understand who we are and what we do?In her words, she asked:"Previously business advice was sell them what they want (weight loss) give them what they need (healthy mindset). How can I position myself in a more tangible way - but without trying to pretend to be a standard nutrition coach? I have a fear that if I'm not selling nutrition or something tangible, no one will understand and therefore won't be interested…."Have you ever worried about this? If you have, you'll want to check out my full answer that will guide you to see the clarity accessible to you right now. ----------
This week we're talking about more of the lessons learned from an increasingly violent America…why you need a “space in your head” to accept that violence could indeed happen to you! MichaelBane.TV - On the Radio episode # 121. Scroll down for reference links on topics discussed in this episode. Disclaimer: The statements and opinions expressed here are our own and may not represent those of the companies we represent or any entities affiliated to it. Host: Michael Bane Producer: Flying Dragon Ltd. More information and reference links: Dr. William Aprill Videos/PDN Tribute Page Gabe Suarez on the Buffalo Shootings “Keep Calm and Shoot Them in the Face”/Gabe Suarez “Speed?”/Handgun Combatives; Dave Spaulding “Facing the Active Shooter”/TRIGGERED SPECIAL, Ed Monk and Tom Givens Intuitive Defensive Shooting/Rob Pincus, I.C.E. Training The Music of Hey Judy The Music of Jake Schlegel
The female brain has the potential to be stronger and better in midlife! Whether you're a woman in midlife or love one, this information is valuable and empowering! And it's all brought to you by the hosts of the Hot Flashes & Cool Topics Podcast, Colleen Rosenblum and Bridgett Garratt! I love to share my favorite things with you, and this is one of them! Check out more about the duo and their show and work in the show notes! First, enjoy the great conversation! LET'S TALK THE WALK! Wellness While Walking Facebook page Wellness While Walking on Instagram Wellness While Walking on Twitter Wellness While Walking website for show notes and other information Coach Carolyn on Clubhouse: @stepstowellness firstname.lastname@example.org RESOURCES AND SOURCES (some links may be affiliate links) DR. LOUANN BRIZENDINE on HOT FLASHES & COOL TOPICS PODCAST Dr. Louann Brizendine's Books The Upgrade: How The Female Brain Gets Stronger and Better in Midlife, Dr. Louann Brizendine The Female Brain, Dr. Louann Brizendine The Male Brain, Dr. Louann Brizendine Hot Flashes & Cool Topics Podcast Colleen Rosenblum and Bridgett Garratt's show can be found everywhere you listen to podcasts! They spend a lot of time with their large, vibrant private Facebook Private Group where all things midlife and menopause are discussed Hot Flashes & Cool Topics on Instagram Hot Flashes & Cool Topics on Youtube Hot Flashes & Cool Topics' Website HOW TO RATE AND REVIEW WELLNESS WHILE WALKING How to Leave a Review on Apple Podcasts on Your iOS Device Open Apple Podcast App. Go to the icons at the bottom of the screen and choose “search” Search for “Wellness While Walking” Click on the SHOW, not the episode. Scroll all the way down to “Ratings and Reviews” Click on “Write a Review” Then you will be able to rate the show on a five star scale and write a written review! Thank you! How to Leave a Review on Apple Podcasts on a Computer https://podcasts.apple.com/us/podcast/wellness-while-walking/id1489506534 Visit Wellness While Walking page on Apple Podcasts in your web browser Click on “Listen on Apple Podcasts” This will open Apple Podcasts and should bring you to the show, not a particular episode Scroll down until you see “Rating and Reviews” You may need to click on “See all” all the way to the right, near the Ratings and Review Section On the right side, you should see 5 empty stars – click on the one farthest to the right if you want to give the show 5 stars To leave a verbal review, please then head left and click on “Write a Review” Thank you! How to Leave a Review on Spotify App on Your Phone Open the Spotify app on your device. Tap the Search tab, then type Wellness While Walking on the search bar; this will lead you to the podcast's show page. If you are on a specific episode, just tap on the podcast's thumbnail and title to be redirected back to the show page. Tap the rating immediately underneath the podcast's description. Alternatively, tap the More (…) icon, then choose Rate show. Drag your finger or tap on one of the five stars to leave a rating. Thank you! The following apps might also allow you to rate and review the show. As of March 2022, there's no way to rate or review a show on Google Podcasts. Castbox Podcast Addict Podchaser Podbean Overcast (if you star certain episodes, or every one, that will help others find the show) HOW TO SHARE WELLNESS WHILE WALKING Wellness While Walking on Apple Wellness While Walking on Spotify Link for any podcast app: pod.link/walking Wellness While Walking website Or screenshot a favorite episode playing on your phone and share to social media or to a friend via text or email! Thanks for sharing! : ) DISCLAIMER Neither I nor many of my podcast guests are doctors or healthcare professionals of any kind, and nothing on this podcast or associated content should be considered medical advice. The information provided by Wellness While Walking Podcast and associated material, by Whole Life Workshop and by Bermuda Road Wellness LLC is for informational and entertainment purposes only. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment, and before undertaking a new health care regimen, including walking. Thanks for listening to Wellness While Walking, a walking podcast and a "best podcast for walking"!
Go to https://tartle.co/university/ Scroll through the page to read more about TARTLE University Click Enroll Now if you are ready to move forward Log in or register to TARTLE This will lead you straight to TARTLE University Packet 1 Watch the video Fill out the form when you're done If you need to navigate back to TARTLE University from the main site, go to the Discover tab and click on the TARTLE University icon Complete the data packets in numerical order Once you are done, email us at email@example.com. Your hard work will get you a certificate, an interview, and maybe even a job!
In this episode the guys discuss the question of God' will in the life a believer. This episode is Part 1 of a two-part mini series. Where do I find what God wants for my life? Is Scripture enough or do I need to search for something more? Do I need to hear from God outside of Scripture? Is God speaking today to us through a still, small voice? A few resources referenced in this episode are: God Doesn't Whisper by Jim Osman (book) Just Do Something by Kevin DeYoung (book) Found: God's Will by John MacArthur (book) ------------------------------------------- To ask a question for the podcast: 1. Go to www.bbcemory.org. 2. Click on the media tab. 3. Scroll down until you see Asking for a Friend! There you will find the box to ask a question!
The first of the Dead Sea Scrolls found in a Torah Ark. Contains the first 8 verses of Leviticus, in basically the Masoretic Text. Incredible technology used to decipher it. God bless you and thank you for listening! Please subscribe and share and leave a five star review!
Harry's guest this week is Rohit Nambisan, CEO of Lokavant, a company that helps drug developers get a better picture of how their clinical trials are progressing. He explains the need for the company's services with an interesting analogy: these days, Nambisan points out, you can use an app like GrubHub to order a pizza for $20 or $25, and the app will give you a real-time, minute by minute accounting of where the pizza is and when it's going to arrive at your door. But f you're a pharmaceutical company running a clinical trial for a new drug, you can spend anywhere from $3 million to $300 million—and still have absolutely no idea when the trial will finish or whether your drug will turn out to be effective. Because there's little infrastructure for analyzing clinical trial data in midstream or spotting trouble before it arrives, some studies continue long after they should have been canceled, and positive data sometimes gets thrown out because of minor procedural flaws; in the end, 20 to 30 percent of the money drug makers spend on clinical trials goes down the drain, Nambisan says. Lokavant's platform allows drug makers and clinical research organizations to harmonize the results coming in from study sites, compare it to data from other trials, and discover important signals in the data before it's too late. For example, a company might discover that it's not enrolling patients fast enough to complete a trial on schedule, or that the researchers administering the study aren't following the exact protocols laid out in advance. Such headaches might sound abstract and remote, but poor data management slows down the whole drug development process, which means fewer beneficial new drugs make it to market ever year; that's the ultimate problem Lokavant is trying to fix.Please rate and review The Harry Glorikian Show on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:1. Open the Podcasts app on your iPhone, iPad, or Mac. 2. Navigate to The Harry Glorikian Show podcast. You can find it by searching for it or selecting it from your library. Just note that you'll have to go to the series page which shows all the episodes, not just the page for a single episode.3. Scroll down to find the subhead titled "Ratings & Reviews."4. Under one of the highlighted reviews, select "Write a Review."5. Next, select a star rating at the top — you have the option of choosing between one and five stars. 6. Using the text box at the top, write a title for your review. Then, in the lower text box, write your review. Your review can be up to 300 words long.7. Once you've finished, select "Send" or "Save" in the top-right corner. 8. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed next to any reviews you leave from here on out. 9. After selecting a nickname, tap OK. Your review may not be immediately visible.That's it! Thanks so much.TranscriptHarry Glorikian: Hello. I'm Harry Glorikian, and this is The Harry Glorikian Show, where we explore how technology is changing everything we know about healthcare.My guest Rohit Nimbasan comes from the worlds of biotech and data science. And during our interview he made an interesting point.These days you can use an app like GrubHub to order a pizza for twenty or twenty-five bucks, and the app will give you a real-time, minute by minute accounting of where the pizza is and when it's going to arrive at your door.But Nimbasan points out that if you're a pharmaceutical company running a clinical trial for a new drug, you can spend anywhere from $3 million to $300 million and still have absolutely no idea when the trial will finish or whether your drug will turn out to be effective.The problem is, there's just no infrastructure for analyzing clinical trial data in midstream or spotting trouble before it arrives.As a result, according to Nimbasan, twenty to thirty percent of the money drug makers spend on clinical trials goes down the drain, because of studies that continue long after they should have been canceled, or good data that gets thrown out because of some minor procedural flaw.Nimbasan is the CEO of a company called Lokavant that wants to change all that.The company is building a data platform that allows drug makers and clinical research organizations to harmonize the results coming in from study sites, compare it to data from other trials, and discover important signals in the data before it's too late.For example, a company might discover that it's not enrolling patients fast enough to complete a trial on schedule, or that the researchers administering the study aren't following the exact protocols laid out in advance.All of those problems can increase the cost of a trial.They can even lead regulators to deny approval for a drug that might have proved effective if it had been property tested.For an average healthcare consumer, these kinds of headaches might sound abstract and remote, like something only clinical trial managers would ever have to worry about. But the fact is poor data management slows down the whole drug development process, which means fewer beneficial new drugs make it to market ever year.So I think we should all be cheering companies like Lokavant who are trying to fix the process.Here's my full interview with Rohit.Harry Glorikian: Rohit, welcome to the show.Rohit Nambisan: Thanks, Harry, for having me.Harry Glorikian: You know, you and I sort of talk off and on all the time about the space and what's going on, but, you know, having it on the show, I have to step back and sort of forget everything I know about the company and start from scratch. So, you know, can you explain to people Lokavant's business in a way that would make sense to someone, say, outside of the pharmaceutical industry. In other words, you know, what are the big problems you're solving for organizations that, say, are running a clinical trial, and how are you solving them?Rohit Nambisan: Sure, I can do that. I think it bears noting that we should probably step back a little bit and talk about the industry as a whole and where it's been going, and then I can clarify where Lokavant comes in. So I think as many folks know and for those who don't, I'll fill in the blanks. I know you know this area, but in the last, I'd say 15 to 20 years, we've been moving in pharmaceutical development away from blockbuster medications, things like diabetes type 2. Right, developing therapies for that and getting each drug developer trying to find a smaller piece of market and larger pie to specialized, niche therapeutic indications. Right. So the way I could probably better started with the diabetes example is it's no longer diabetes type 2. It's let's develop the compounds or therapies for diabetes type 2 patients that are comorbid with that have also chronic kidney disease and are metformin naive, meaning they haven't taken a particular therapy known as metformin. Right. So it's a more complex filter criteria, so to speak. Right. And so what happens when the industry moves in that that direction is that when you get into these very niche therapeutic areas, you need to collect particular niche, commensurately niche types of data to validate your hypothesis whether or not this therapy is safe and efficacious through clinical trials. Right. Rohit Nambisan: And in doing that, you now increased the complexity of the trial greatly, not only in terms of the different types of data collecting, but the amount of different types of data you're collecting. So now each trial becomes a lot more specialized. Not just specialized therapeutics, but each trial becomes more specialized. Right? And so for that reason, we've seen a big challenge as we as we moved across that space. And actually, it's been really beneficial for patients because now we're going after, as an industry, we're going after really niche unmet clinical needs that previously there were no therapies for or being developed for. So it's a really good thing for a patient perspective, but from the perspective of development, it makes it that much harder. Not only is there a smaller market opportunity, there's less patients to treat, right, but the complexity, the actual costs of the trial and the complexity of trial has gotten exponentially that much greater. So what Lokavant came out of was we were actually a, shall we say, an internal initiative within Roivant Sciences, which is a company that launches a number of different biotechnology companies and tech companies as well. But better known for biotechnology companies. And we saw a great need to be able to develop therapies for niche indications much faster, much more efficient, much more cost effectively, and also meet the complexities of that trial better through novel data and tech.Rohit Nambisan: And so what Lokavant is essentially, is a data platform that allows drug developers, pharma, therapy developers, to be able to choose which data sources they need, data types they need for a trial. And we can ingest any of those data sources, we can analyze any of those data sources in a holistic manner and expose patterns or signals that could be beneficial or detrimental to the study on an ongoing basis. And when I say ongoing basis, I mean you're not waiting until the end of the study. And I guess the best way I can align this is just like my kids do sometimes. You're not waiting until the last day before your term paper is due, before the project's due to finish your work, you're actually assessing, doing bits of it along the way to assess where there may be challenges, which gives you, really, the time to correct issues to manage your trial better. And frankly, each one of these trials now, there are between, what, $2 million and $300 million we're investing in these single trials at this point. So it's egregious to me that we do not have the toolset to be able to even identify, pull in that data effectively on an ongoing basis to detect these signals so we can plan effectively to do something about it.Harry Glorikian: Anybody who's done a clinical trial knows that there's a lot of risk. Right. So, you know, can you talk about some of the types of risks you're trying to help make sure drug developers diminish, for the most part.Rohit Nambisan: Yeah. So I think the way we start with that is always at the highest level, time, cost and quality, right? So when we talk about time, it's really important to understand that you're going to be able to achieve less. For example, I'll give you a few instances. Target participant accrual, right? Obviously for you to run a trial effectively, you need to have particular types of participants or patients, if it's a sick population. In a vaccine population, they weren't necessarily sick. So that's why I use participants as the term. But you need to make sure that you have path to randomized screening and randomizing these patients for your trial in a given time period. Right. And if that's if your enrollment is is not on track for the countries and the sites you've decided to actually activate the study in, you could, your timeline for your study could be exceptionally extended. Right. So that's that's one type of one example of a thing we look at to understand how the timeline looking for the study. Another area on timeline for example and similarly is discontinuation. So you can you could enroll patients fine. But if you've high volumes of discontinuation of participants in your study, then what ends up happening is you actually don't have as many evaluable subjects in your study of some evaluable participants. So you have to recruit or enroll more subjects, right? So that could extend the timeline as well. One aspect of the timeline that really affects the overall market opportunity is oftentimes these therapies are only in under patient for a certain amount of time. So the faster you can get them to market, the faster you can get recoup your return on investment. But also on the patient side, the faster we can get these therapies out through the market to address unmet clinical needs. That's just one flavor.Rohit Nambisan: Then we have subsequent types of flavors. When we talk about data quality, making sure the data is actually collected in the way that you stated you wanted it to be collected in the plan and the protocol at the outset of the study, as well as cost implications. Right. So we look at cost implications as well, which is how, what will this, what will the extension of enrollment or bad data quality data do to the overall budget that you had planned for this study? But then when you drill down on the level further, you can get into risk categories, is something we look at quite a bit when we look at things like protocol, adherence, when you're when you're collecting this data, as I mentioned, it has to be done per a very prescriptive method that is specified a priori before starting the trial in a protocol. And if it's not collected in that manner, it can be discounted. So we are tracking the risk to protocol deviations and understanding trends and not only understanding trends within that study, but we're looking at similar types of studies in this particular therapy area, neurology or say, psychiatry or gastrointestinal type studies and saying, what has been the protocol adherence in studies like yours? And therefore, can we glean some insights about how you are doing in your study based on your comparators in the study as well? But that's just a small flavor. I could probably wax on for quite some time on this question.Harry Glorikian: Well, that that brings us to the question -- I mean, everything you just said, it brings to the question like, from what I know, the company sort of predicts how clinical trials will go by comparing it against a proprietary data set of, I think I was reading, 2000 past trials, right? So I guess the question becomes, so you're comparing one to the past of things that are similar, but you know, for everybody who's listening sort of, you know, where does that data come from in one sense, is it truly proprietary? I mean, that's what I'm you know, that's my set of questions at the moment.Rohit Nambisan: Sure. So I worked for a while, before coming to the life sciences, in the R&D space and the life sciences commercial space. And I think that data sets, are there are proprietary datasets in that space? Very much so. But there is a third party market for that data a little bit more. So then we find life sciences data. It's really hard to get access to R&D data and as you can imagine, that makes a lot of sense, right? If you're a drug developer or a pharmaceutical developer that successfully completed a trial, you never want to share that data. Thereafter, you spent millions of dollars investing in the study, if you want. If there are potentially unknown issues that you haven't identified, would you want to put that at risk? If you are similarly, if you are a therapeutics developer that didn't meet your endpoints, do you want that information to get out and maybe potentially things that issues that that you should have should not overlook, right, getting out in public, etc.? There's just a lot of business risk. There's also IP risk, right? There's a number of different risks associated with getting that data out. So it's been not a very straightforward journey to aggregate data in life sciences, R&D. That being said, I think how we approached this was we've developed models that are both used for benchmarking, as I mentioned before, comparing against similar trials for particular performance KPIs, so to speak, as well as predictive model generation and machine learning models that require a fair amount of data to train on to actually deliver value.Rohit Nambisan: And in that model, we've talked to a lot of our partners or let's say folks that leads them before their partners. And we talk to them. We say we have a growing dataset. There's precedent for this because we've done this with other partners, number one. Number two, we've worked with them to leverage their data combined with our data, write their enterprise data with our data, because it's a common, it's not just one entity's data that's going to provide that value. Your performance, your processes, the way you run trials is inherent in your data. And if we don't leverage that data to train our model to retrain some parts of our models against, we're not providing you the most value we could be with our predictive models or benchmarking. So with that approach, we've been able to do comparative analysis of our data set versus other people's datasets and then anonymize their data upon having a partnership with them to grow our data assets in a very risk-tolerant manner. Right. All the information about CROs or sponsors or other entities, people running trials is removed from the data and we only leverage that data for the purposes of analytics or generating a benchmark. So none of that data is ever shared. So through that process, over the last, I'd say two years, maybe a little two years and change since we started, we've been able to continuously grow this asset and provide greater and greater value with our descriptive diagnostic predictive analytics as well as our benchmarking.Harry Glorikian: How much money, if you had to guess just to give people like an idea, how much money do you think gets poured down the drain preventably every year, and you could save all this money if you just ran smarter, if you did smarter clinical trial management, if I had to frame it that way.Rohit Nambisan: Oh, at least I would say we've done some back calculations on this and happy to digress into the details of them if warranted, but at least somewhere between 20 to 30 percent of the trial costs right now and depending on the phase and depending on the therapeutic area, again, that could be anywhere from 20 to 30 percent of $3 million to $300 million per study.Harry Glorikian: Yeah. I mean it's you know, that's got to be, I don't know how many billions that is. I can't I don't know exactly how much is being spent annually off the top of my head.Rohit Nambisan: We believe we've done some back of the envelope calculations to show that it is in the billions for sure. Across the across the global pharmaceutical market, we're looking just just the value proposition and the signal detection we're bringing to bear is somewhere around $18 to $20 billion, in terms of market opportunity.Harry Glorikian: I mean, how would you guys run or help a team run a clinical trial in practice? Can you sort of give me a real-world example, maybe de-identified, where you helped the client avoid or mitigate some kind of risk, whether it has to do with patient enrollment or site compliance or safety issues during a trial, any one of those will do.Rohit Nambisan: Sure. So I think one example that I can bring to bear is working with a large CRO. And with this large CRO, they had a sizable data asset that was not harmonized, so to speak. It was still living in the transactional exports from the source data systems or CSPs. Et cetera. All around. So it was they had a bunch of different hypotheses about where they were proficient, where they were deficient, but nothing validated. So we spent some time with them trying to understand what all their data assets looked like. And we started collecting these different representations of former trials and ongoing trials, and we collected them and we harmonized them. In fact, as I mentioned before, one of our major differentiators is this is creation of a single source of truth. And we take that upon ourselves, too. It's not like a service, it's part of our offering, right? Our platform offering. And so what we did was we brought that data together and we it was about, I think 400 to 500 studies worth of data at that point. We harmonized it into what we call our local and canonical data format, which is a single representation for multiple different domains of data, scientific data, operational data, enrollment data, etc. And then we compared that against similar studies in our repository, our growing repository, and said, okay, we can tell you comparatively that you are deficient in these particular areas and you're very proficient at the various--for example, in this case they were very proficient in achieving first patient in on the timeline that they expected to actually, scratch that, that they were very they were very proficient in actually accruing the subjects by last patient in in the time they were expected to write so they could hit their accrual when they wanted to.Rohit Nambisan: But when we looked deeper into the data and looked at across like first patient in, the 50 percent enrollment mark for the study and then last patient in for the study, we were able to identify that there was actually a slowdown and a major overcorrection to make up for that. So they were actually hitting what they needed to hit. But as we all probably know, at least in the clinical research phase and any or any budgeting process, being over your budgeting process is bad. Being under your budgeting process is bad, right? So in this case, it's again the same. They were burning resource and cash and resources to rapidly overcorrect for for a milestone they were not hitting reliably earlier in their studies. And so we realized in that accrual situation we said, okay, what you need is, we've identified an error, you're potentially deficient. What you need is an enrollment forecasting application that brings in the data in real time from your study. Right. And it also combines historical data from our repository in your historical data to seed some prior knowledge about the study. So and it's automated, fully automated. So every day you can understand where you are in relation to where you need to be. Right? And it's not a naive straight line kind of curve. It's basically it's based on looking at thousands of historical studies in this space and understanding what the curvature of the actual model should look like.Rohit Nambisan: So we generated that and we were able to actually, in the proof of concept, and this is just one particular example of an application we've been able to generate from our clinical trial intelligence platform, we generated that and we were able to, on a study, predict two years out within one month when they would actually really hit the accrual and it was within one month accurate. Now while that was valuable in terms of understanding at the end state, what really the value was of this closed loop model, so to speak, right, is that it is closed loop. It allows them in silica to say, what happens if I open some sites here? What happens if I close some sites? So what happens if I close this country here? How will that affect my plan before I put that into action in the real world, which oftentimes is very, very, first of all, it's very risky. But second of all, it can yield a number of unknown consequences if you don't try it before in silico. So I think the approach here was we were able to not only predict these things better and also predict the impact of change orders on the study, that might actually affect the timeline of the study. But we were able to actually provide them an application, an interface by which they could test it all their hypotheses in a virtualized manner before they implemented them. And we're growing like crazy with that, with that partner right now at that point.Harry Glorikian: Yeah. And I mean, I mean, you know, in some ways it sounds like, you know, I didn't get it done and I'm pulling all nighters, like at some point so that I can get it done. Right. So there's a whole staffing model. And how do you bring this to the attention of everybody so that they don't drop the ball? Right, because there's a million other things that might be coming at them at that moment.Rohit Nambisan: That's exactly right. Actually, one thing I'll add to that, given you mentioned the staffing model around it, is that we were born within small biotech. Right. And small biotech is very resource-constrained in its ability to manage and oversee a study. That's fairly well known. So our approach has always been what I'd like to call machine-assisted human intelligence. We have experts that are human experts that know the space, but they need to be augmented. They need to be able to look at more complex streams of information and have a machine pick out particular salient insights, salient information, and provide that to them so they can process it, reducing degrees of freedom for them to process it.Harry Glorikian: So just I mean, there are a lot of statistical tools out there now that that for managing risks in clinical trials. So how is the approach that you guys are taking either different or better or both.Rohit Nambisan: It's a good question. One way we've been able to address this question is that statistical approaches generally require certain amounts of data points to be collected before you can warrant using statistical parameters or assumptions, etc. And so there's two things at play here. On top of that, I just mentioned, we're moving into more specialized therapeutic areas, right? So patients per study are smaller, right. And on top of that, when you're starting out a study which is usually the riskiest points in the study, when you're early in the study to mid-stage in a study, you cross them with the fact that you have less patients and there are more niche studies, it's hard to find those patients. Now, your early phase, your riskiest phase, is going to be extended as compared to when you were developing against blockbuster indications. So for a long time in the study, you can't really reliably use statistical parameters to identify an outlier or identify something as aberrant. And then you need to focus on so the way we've done it, we've done it in a slightly different way. There's two approaches. One is we've actually developed a pretty complex risk score system that's based on a set of very different metrics. Think of it as like an array of different KPIs, right? Those KPIs will affect risk differently depending on the type of study you're in. And they'll have different weights to those risks of time, cost and quality depending on the study you're in. So we look at the given study, we're going to deploy and we say, okay, what are the features that characterize the study? Let's look in our historical repository against those same features, pull similar, we call look alike studies and we'll understand how to set those weightings to say protocol deviations at this point in the study are going to impact the overall quality of time. That's much more for this type of study. So we can basically, for lack of a better term, I guess the simplistic way of saying is we can augment the data that we have coming in from a study, which is small at the outset of the study, with lookalike data to increase the power. Right? So that's another way to look at this. So we can actually, we have much better power to be able to detect these issues earlier on and reliably confer that to clinical operators and clinical developers who can do something about it.Harry Glorikian: It would be nice if you had enough data at some point to almost run the whole trial in silico, in a sense. But I think we need a lot more data get there. But, just for everybody that's listening, sort of as a philosophical point, the reason we put drugs through clinical trials in humans is we simply don't know whether they'll work or what the unexpected side effect they might have once you start them on a much larger population. So in that sense, it's expected, even normal for some drugs, maybe even a lot of drugs, to fail at some point in phase one, phase two or phase three. And as an investor, you know, you don't want it to fail in phase three. You want it to fail early. So is Lokavant's goal to reduce the failures or simply help drug developers get to yes or no faster, safer, more cheaply?Rohit Nambisan: Yeah. So our approach has been initially get yes or no faster, safer, more cheaply, more efficiently, right. As part of that process and actually related to some of the work we have done in the last few months on monitoring scientific risk. Right. You have to be careful about these efficacy analyses because they can unblind the study, especially when you have single or double blind blinded studies. So you have to be careful about this point. But in some circumstances we can actually leverage our analysis on blinded endpoint analysis and understand how particular endpoints are collaborating or not collaborating or trending, to understand if there is any effect whatsoever that's being generated in the study. So this is early days for us. But to your to your point about the first use case, we are starting to think about that as an opportunity as well, because we found a way to effectively blind the information and still assess the information content to understand if there is any form of efficacy signal being produced. So I think that that is a really valuable way for us to approach the market in the near future. I think the other point here is that if you are cleaning the data, if you are identifying those data quality issues on a more real time basis, you should be able to reduce the time to do an interim analysis. Right. We should be able to -- you mentioned fail fast. Right. Failing fast requires you to also assess the data, to understand if there's an efficacy signal, there's a safety issue. And if we have these long cycle times before we can actually do an interim analysis. And much of the data indicates that those long cycle times are due to not knowing where the issues are and finding those issues then cleansing them. If we can do that faster, we should be able to do interim analysis much more frequently. Therefore, being able to generate a fail fast scenario.Harry Glorikian: You could almost, you should be able to set up the system to almost be running it and sort of move the bar on where it is on, “Looks successful,” or “It's moving down towards failure.” There's got to be some sort of almost real-time indicator as data is coming in to. You just don't want humans to jump the gun on that. The interesting thing is, I was looking at one of the blogs you have and you sort of say that one of the main reasons clinical trials are so costly and inefficient is bad data management and a lack of interoperability across data repositories. And, you know, it's funny because anybody who listens to this show knows that just comes up over. And it doesn't matter who you are in health care. It is a recurrent theme that for some reason people are not willing to step up and solve. I mean, it has to be a party like yours that comes in and helps clean it up from the outside as opposed to it being cleaned from the inside the way that you would ideally like it to be.[musical interlude]Harry Glorikian: Let's pause the conversation for a minute to talk about one small but important thing you can do, to help keep the podcast going. And that's leave a rating and a review for the show on Apple Podcasts.All you have to do is open the Apple Podcasts app on your smartphone, search for The Harry Glorikian Show, and scroll down to the Ratings & Reviews section. Tap the stars to rate the show, and then tap the link that says Write a Review to leave your comments. It'll only take a minute, but you'll be doing a lot to help other listeners discover the show.And one more thing. If you like the interviews we do here on the show I know you'll like my new book, The Future You: How Artificial Intelligence Can Help You Get Healthier, Stress Less, and Live Longer.It's a friendly and accessible tour of all the ways today's information technologies are helping us diagnose diseases faster, treat them more precisely, and create personalized diet and exercise programs to prevent them in the first place.The book is now available in print and ebook formats. Just go to Amazon or Barnes & Noble and search for The Future You by Harry Glorikian.And now, back to the show.[musical interlude]Harry Glorikian: So on this show we talk about, you know, how does analytics play into this? So, how do—and I've got to start finding new words—but AI and ML come into this picture. What types of tools in the AI toolbox is Lokavant using? What special powers does AI give you to extract predictions from your data set that other people don't?Rohit Nambisan: Yeah, I think I think the first piece is, and it's going to sound interesting in relation to what folks usually talk about in terms of AI and ML, but it's a harmonized data model, right? When I was working as a data scientist a number of years back, nobody told me all the work that you have to do with data governance and data harmonization. And then when you think about fast forward today where a lot of the actual models themselves are function calls, right? You realize that a lot of the work is actually making sure that data is ready to be analyzed for this particular use case. Right. So it's not to say that we don't do a number of different, try different approaches to gradient boosted descent or support vector machines or neural nets, which is actually my background in terms of grad school and research. But we spend a lot of time thinking through how we need to harmonize, create validated data pipelines to harmonize data for use. In this case. And even in that case, a lot of the work we do is a kind of intelligence or artificial intelligence. So when we're harmonizing the data, we're looking for views on leveraging multivariate clustering algorithms to actually figure out which particular types of data attributes should be mapped to one particular field.Rohit Nambisan: So it's not to say that the data harmonization is devoid of intelligent approaches, it is full of intelligent approaches, but it is an absolute necessity to have the integrity of the data that you need to run those sophisticated front end models, which we run a ton of. But I just I want to call attention to the fact that that is a core asset for Lokavant from the get-go, that Lokavant's canonical data model and the processes we use to harmonize data to get it into that state has been a core focus because if you can do that—and that is the same model you're providing to your data science and analytics teams, your product development teams—then you really have that flywheel that you can generate a number of different analyses. For example, I just mentioned that predictive enrollment forecast model that comes off of in our our Lokavant canonical data model. That is something that is a predictive model, leveraging historical data and ongoing study data in an automated model that indexes towards the historical data early in the trial, indexes towards prediction indexes towards ongoing study data as it comes in. And we have more confidence that input over the trial, that's like an emergent benefit of having the harmonized data harmonize.Harry Glorikian: So, you know, one has to ask in the age of the coronavirus, right, how has the business of running clinical trials changed since the pandemic? I mean. And how do you guys...is that an advantage or disadvantage? I'm trying to, you know, place where you guys are in the whole realm of how things have hopefully changed for the better.Rohit Nambisan: Yeah, it's been quite a tailwind for us actually. And I would say that, number one, it's been it's been beneficial to us because there's just been a lot more scrutiny and interest in clinical research. Not to say there wasn't before, especially for niche therapeutic areas, but and the fact that we were able to develop and get novel COVID vaccines out pretty rapidly. But there was also a lot of challenges along the way in getting to that point. And also delays and trials and challenges in therapeutics development to address COVID as well. So there's just been a lot of scrutiny in the last 24 to 30 months on how efficient and how fast and how effective clinical research can be. So just that alone has been beneficial. Now let's take the next step there and say that all associated with the pandemic, there's been a great impact to clinical trials across the board, not just COVID trials or therapeutic trials. Patients, participants couldn't get to sites for site data collection, right. Site staff couldn't get in there, too, for data entry or site management or site oversight activities. Right. So in general, it's been a huge boon to those technology groups that have developed, decentralized or direct-to-patient data capture methodologies, thereby lowering the patient burden and the site burden for clinical trials to continue in a pandemic fueled environment. What's interesting about that as well, when we think about ourselves as both a data type agnostic platform for clinical research as well as an analytics engine, a platform on top of that, you see this huge movement to another type of data, another data, for example, decentralized trial data as another data source.Rohit Nambisan: And what we've seen also is that while there's been a shift to a lot of decentralized trial collection on most studies, at least 90 percent of studies and above, they're hybrid, they're not fully decentralized. So you have to have some site data collection and you have some decentralized data collection. And that makes sense for those things that may make the most sense to lower patient and site burden to administer. Let the patient let the participant be at home. For those that require like biopsies, etc., that require a participant oftentimes to come into the site, let that be the site. The challenge there is now you have these two different complex data streams that are not necessarily harmonized and aggregated. So this is, again, I think that's been an area where we've been able to come in and say we'll just as a matter of course, you're doing business, this is another data set to us. We need to bring these two in and we have to also enable comparative analysis against decentralized and traditional site based data collection, because otherwise you're going to miss insights. You're going to miss information that are critical to your study.Harry Glorikian: Yeah, a part of me was just thinking, you know, you guys should buy somebody, like Unlearn AI and go at it together where you can have, you know virtualized patients that you can put into the trial, but that's… we won't go there. So let's step back for though, for a second. So let's talk about the company's origin story. Lokavant is one of many companies launch by Roivant, as you mentioned earlier. A Lot of the companies end up with the word “vant.” So can you explain so that people understand: What is Roivant, how it operates, what are vants and and why was Lokavant born. And how did you become president and CEO?Rohit Nambisan: Sure. So Roivant started about seven years ago. And I should mention Roivant is our parent company. We were founded out of Roivant and spun out as a technology company itself. So Roivant initially started as a company that launched "vants" -- nimble, entrepreneurial biotech companies and now health tech companies as well. When I joined Roivant three and a half years ago, Roivant had about 15 different biotech companies. And what was really interesting about their approach is it was therapy agnostic, so it was not that there was a strategic focus or oncology or strategic focus on immunology. There was a focus around identifying compounds that may have been deprioritized in larger pharma companies, which says pharma companies that had a lot of potential and had could address critically unmet clinical needs. And so Roivant would in-license those therapies and start a therapy therapeutically oriented vant. So at the time Axavant it was the new neurological oriented, neurological disease oriented vant. Myovant was the human reproductive oriented, disease oriented vant. Et Cetera. And so now when you think about somebody like myself who comes from the tech world and life sciences, health care technology world, brought into Roivant three and a half years ago, the premise behind Roivant at the time was we can more efficiently develop these therapeutics and have more favorable outcomes leveraging innovative ways of addressing human talent as well as technology. And that latter piece is where obviously I came in and we were starting to look at in my team what are some of the most significant challenges and frequent challenges amongst the vants themselves in running these clinical trials? And then does that map against some of the more significant frequent challenges we see outside in the market? And not surprisingly, there were quite a few particular areas of resonance.Rohit Nambisan: At that point in time, they're about 54, 45 programs being run by Roivant. And so it was across a variety of therapeutic areas. And I guess the thing that hit us in the face primarily was I guess the best way I could say it is you can order a pizza, right? You can understand what is it, a $25 investment, $20 investment. Maybe it's gone up since then, since I ordered a pizza. But the point is that you can understand what time it was ordered, when it was when they said they were going to deliver it to you, and you can track it. And most of these apps now [show it] along its destination to a chain of custody to get to you. We were we could spend $3 to $50 million on any given trial and we were at struggling with our partners to actually identify what is the current state of enrollment in the last week? What is the current state of discontinuation? Where are we at with our with these particular sites in this region? Why are we seeing high screen failure rates, etc.? Right. That's egregious to me. That's just that should not be the case.Rohit Nambisan: We are fairly frustrated with that. And then even when we when even at Roivant or even in my former experiences at Novartis or other pharma, when we brought in a source system to say, okay, well, we're going to have a representation of data ourselves, right? So that we can understand what's going on. Invariably what happened is you would have one source system here and then a duplicate version of that sort of system at the CRO or another vendor that's working with you. You spent your entire time trying to figure out which was the source of truth, because they're spending all your time doing data reconciliation, saying, is that really accurate? Is that really the signal? So that didn't work either. So we felt pretty frustrated about this. We initially tried not to build it ourselves. We worked with a few different collaborators outside of Roivant and tech vendors, etc., and we were fairly frustrated with what we came back with there. So at that point we started thinking, if we can't buy it, we need to take a lead user innovation approach to address this. So we started out with the data platform, as I mentioned to you, and we built that capability to connect, ingest and map from any source, deliver that within a canonical data model, one single canonical data model. And then initially we did a bunch of bespoke analysis on top of that for a few different biotech vants. Rohit Nambisan: That went really well. Some of the external collaborators looked to Roivant at that point we said we'd like to work with this technology outside of the Roivant family, and we realized we were on to something, and we externally launched the company in January of 2020, which was very interesting time and year to launch a company. That being said, we spent the first, I'd say, just under two years, really focused on externally subsidized R&D phase. We're pretty fortunate to have some partners that invested in us in that phase, and we focused on first one particular application in response and we talked a lot about risk. But then we also realized that the needs across different companies, different vendors, etc. for managing clinical trials are very varied. So we realized what we need to really build as generalized on that first application we built and create a highly configurable analytics platform on top of this data platform so that we could actually analyze many different things and configure it for use for any particular customer. And so now we built across, I'd say seven or six or seven different use cases now, and we've deployed most of them and we're continuing to aggregate information in a true product sense where the biggest pain points in the market and how do we build or configure a version of the platform and the platform to address that. And at the same time, we're delivering on global trials with a number of pharma studies as well as on the side of the vendors working through them to deploy on studies as well.Harry Glorikian: So in a perfect world, right, if you had access to all the relevant data, if every drug developer in the world was taking advantage of your services, how would it change the business of clinical trials? What would the outcomes look like? Would it be like you get more drugs approved every year, at a lower cost, fewer disaster failures, I mean. What changes for the industry and for patients?Rohit Nambisan: Yeah. I think the first piece is you would reduce—and this is a lofty question so I'm going to answer with a lofty response—the first thing to note is that, and we touched on this earlier, I think you'd see fewer bigger failures in the analytics phase. You'd be able to identify earlier on, both in terms of the lifecycle of a compound, right? So from phase one to phase three or even phase four, but especially within the study itself, you'd be able to identify that there would be an issue in the study earlier on and you could kill it early on. So that's one one aspect I think would be that's important to note. The other thing I think you would identify is less operational issues. So I think one in six trials across the globe failed just because of operational issues. And when I mean operational issues, I mean the protocol and the plans at the outset of a study say need to administer the study following these steps. And when those steps are not followed, there's compliance risk. And therefore, when there's enough compliance rates to throw out the data or you have to not submit the study.Rohit Nambisan: And so one in six is, it's not that small. And so if we're tracking, if we're more rigorously tracking both what is happening and what could happen, right, based on the indication, leading indicators of risk across time, cost and quality, we should basically never see -- that's a that's one of our major goals -- never see a trial fail just because of an operational reason. Not to mention, how can you go to the patients with unmet clinical needs in a particular indication in particular disease and say, “Oh, I'm sorry, while the drug probably was effective, we just couldn't get it out into the market this time. And it's going to take us another trial, potentially.” A lot of times folks don't actually resurrect the failed study, a failed therapy. So even if they resurrected it and said it was because of an operational issue, “Oh, you've got to wait another six years.” That's just not acceptable. So I think those are the two components that come top of mind. And I think early in our in our tenure, our mission was no trial should fail due to operational error.Harry Glorikian: What is the path to financial success for a company like Lokavant? Is it to just keep growing? To go public? To get acquired by a maybe by a big pharma. What's the path?Rohit Nambisan: It's a good question. I think folks that that know exactly what their exit strategy are probably, for lack of a better term, often deluded. But I will say that we've seen a lot of growth. Not only during, there's been a lot of interest in Lokavant during the pandemic, I mentioned we were in this externally subsidized R&D phase, we were actively trying not to do too much externally. We wanted to figure out how to set up the platform for success. Coming out of that phase, in the last six months, we've seen an incredible amount of traction externally. And so I think we are still in the path of doing it on a growth trajectory ourselves. What does that mean in terms of opportunities to collaborate both commercially and partner and strategically? Well, it means that we can only do as much as we can, even if we continue to grow. There's data out in the market and partners that have access to that data that we would love to collaborate with. If that means that we need to be more strategic in our approach to what Lokavant can do or how to structure Lokavant, we'll do that just because we need to actually achieve our mission, which is to have no trials fail due to operate operational error. Right. And so I think that requires more data. That requires more data science. We have a lean, very, very proficient data science team. So I think there will be opportunities for strategic collaboration, but it's all related to the mission of bringing this clinical trial intelligence platform to address operational and other risks in a study as effectively as possible.Harry Glorikian: You know, one of the things that crosses my mind is you could also use this from an investing perspective to analyze a trial that's going through its paces against historical information and determine, give it a weighting of probability of success versus failure from an investment perspective, that that seems attractive to me.Rohit Nambisan: Yeah. So that's an interesting point to bring up. There are folks now asking us in the market about what we've been informed firmly in trial execution stage. Folks are asking us to move into feasibility and effectively feasibility. Is that the planning of the study? Tell me with this particular configuration of sites, countries and for this indication, knowing the standard of care in different countries, knowing the approach to clinical care, not just clinical research, how successful would this study be? Right. And obviously, the success of a study, when you think about biotech, the success of a study is the success of the company. When you think when you go up the market, depending on the study, it can still have incredible impacts, the success of the company. So there is definitely an afferent towards the investing world and financial. I think at first we probably take a progressive step towards that by moving into trial planning analytics in this manner and then validating our approach against progress in space and seeing how we can continue to grow in that sector.Harry Glorikian: Well, Rohit, it was great having you on the show. I hope everybody enjoyed our discussion. You know, a lot of problems to solve in this industry. So there's there's no lack of opportunity from, you know, businesses that need to get started and the data that needs to be optimized to help move the process forward. But, you know, luckily, everybody I talk to on the show, that's the direction we're all moving. So hopefully we'll get there faster, because I'm not getting any younger. So, so good drugs are going to be needed at some point. So good to have you here. And I can't wish you and the team at Lokavant, you know, more success.Rohit Nambisan: Thanks, Harry, for having me on the show. It was wonderful to be here.Harry Glorikian: That's it for this week's episode. You can find a full transcript of this episode as well as the full archive of episodes of The Harry Glorikian Show and MoneyBall Medicine at our website. Just go to glorikian.com and click on the tab Podcasts.I'd like to thank our listeners for boosting The Harry Glorikian Show into the top three percent of global podcasts.If you want to be sure to get every new episode of the show automatically, be sure to open Apple Podcasts or your favorite podcast player and hit follow or subscribe. Don't forget to leave us a rating and review on Apple Podcasts. And we always love to hear from listeners on Twitter, where you can find me at hglorikian.Thanks for listening, stay healthy, and be sure to tune in two weeks from now for our next interview.
The habit of meditation is such a beneficial one that we talk about so much in this podcast. It is something that can be such a game changer. It allows us to find clarity in our lives as we move towards balance and as we analyze the guilt we feel as parents. In this episode, Felica talks with Kelly Smith from Meditation Mamas Podcast and the Mindful in Minutes Meditations Podcast. She delves into how she makes her meditation practice actually happen while still being a parent. YOU CAN FIND MORE FROM KELLY SMITH HERE: Meditation Mama Podcast Mindful in Minutes Meditations Listen Notes:) RELATED EPISODES Finding Motivation to Claim Your Personal Power Hour Make Your Morning Routine Happen! Morning Routines for a 30 Day Transformation with Taralyn Hone Your Morning Routine with Felica Our Daily Meditation: this is the meditation that Taralyn does every morning. You simply push play and she walks you through it. It's an easy way to get yourself into the habit. Breathwork Exercises for Daily Habit Building with Taralyn The Artist's Way // Julia Cameron YOU CAN FIND MORE FROM KELLY SMITH HERE: Meditation Mama Podcast Mindful in Minutes Meditations Listen Notes:)Thank you for the kind reviews! We appreciate them so much. Here is how to leave a review for us on iTunes: Open Find the Magic in the podcast app Scroll to the bottom of the page Click on write a review Tap the stars to rate us and then write us some feedback:) Hit SEND Review of the Week from Nikkiex0 I love this podcast and I appreciate the hard work that goes into every episode. I just can't imagine life as a parent without any guidance, and I feel like the hosts are my weekly guides. I'm blown away with how many valuable resources I find in each episode. As mentioned in the intro, they literally do all of the hard research on parenting and distill the information through the podcast. I'm a mother of a 4 and 6 year old and I wouldn tfeel as confident and grounded in my motherhood journey if it wasn't for the resources provided by you ladies. I love this podcast so much I often find myself craving a second episode each week. Thank you, Xoxo --- Support this podcast: https://anchor.fm/findthemagic/support
Have you ever struggled with identity, worth, and significance? In this episode, my guest, Tina Yeager, shares about discovering your true worth, value, and significance in Christ. She wants you to know that you are a beautiful warrior who is loved by God and to believe the truth of who God says you are while dispelling the enemy's lies about who you are not. Tina shares about her battle with anorexia and how she found healing in Christ. We're talking about spiritual nourishment and helpful steps for healthy spiritual living. I know what Tina has to say will encourage, inspire, and challenge you--so listen in while I have a chat with Tina Yeager. By the Way... Fierce Calling is on the Spark Network which can be found on the Edifi App! Fierce Calling is one of many Christian podcasts available on the Edifi app. To listen to this podcast and other amazing Christian podcasts, go to the Apple or Google Play stores and download the app today! Favorite Quote from Discovering Your True Worth, Value, and Significance in Christ... "...just know that you are loved--that Jesus would have died if it was only for you and that's how much you are loved..." --Tina Yeager Connect with Tina! You can connect with Tina at tinayeager.com, check out her podcast "Flourish-Meant" and grab her book... by Tina Yeager More about Tina... Tina Yeager Tina Yeager is first and foremost a beloved child of God, wife, and mom. She's an award-winning author, inspirational speaker, life coach, and has been a mental health counselor since 2005. She hosts the Flourish-Meant podcast and publishes Inkspirations Online, a weekly devotional for writers. Her fiction and nonfiction strive to clarify how we might relate better to others, to ourselves, and to God. Let's Stay Connected! Scroll down and grab my free resources and when you do, you will also receive my free monthly newsletter with more encouragement! Love Fierce Calling? By following, rating, and leaving a review over at Podchaser, Apple Podcasts, or wherever you listen to podcasts you can help others discover the show too! Do You Need a Speaker for Your Next Women's Event? Check out my speaking page, grab my flyer, and let's talk about me speaking at your next women's event... I love speaking God's truth into the lives of women! Free Gifts for You... Grab one of my free downloads by scrolling down to the bottom of the page! Love & God's Perfect Peace to You!
#adafruit JP's Product Pick of the Week 5/24/22 ANO Navigation Scroll Wheel Encoder and Breakout DEEP discount during the livestream here! https://www.adafruit.com/product/5001 https://www.adafruit.com/product/5221 Visit the Adafruit shop online - http://www.adafruit.com ----------------------------------------- LIVE CHAT IS HERE! http://adafru.it/discord Adafruit on Instagram: https://www.instagram.com/adafruit Subscribe to Adafruit on YouTube: http://adafru.it/subscribe New tutorials on the Adafruit Learning System: http://learn.adafruit.com/ -----------------------------------------
#newproductpick JP's Product Pick of the Week ANO Navigation Scroll Wheel Rotary Encoder + Breakout PCB RECAP https://www.adafruit.com/product/5001 https://www.adafruit.com/product/5221 Visit the Adafruit shop online - http://www.adafruit.com ----------------------------------------- LIVE CHAT IS HERE! http://adafru.it/discord Adafruit on Instagram: https://www.instagram.com/adafruit Subscribe to Adafruit on YouTube: http://adafru.it/subscribe New tutorials on the Adafruit Learning System: http://learn.adafruit.com/ -----------------------------------------
A tiny kitchen. No oven. A miniscule fridge. No electric power. A small two-burner hob. Prep space the size of a chopping board. Lots of us think we have small kitchens, but imagine cooking nutrient-dense food in these circumstances. That is exactly what our guest, Charlie Burton did - for her, her husband and their two young children...for two years! And all whilst travelling around Europe in a van. Listen into this episode to hear: How Charlie cooked three meals a day and lived in a six-and-a-half metre long van and what advice she'd pass on to all of us with limited space. How she managed to find really good food on the move, despite the cultural and linguist challenges. The beautiful food highlights of her trip, including an amazing ancestral-style heaven in Slovenia. How she regularly made pizza without an oven! The constraints and restrictions she experienced on the way and how both of these things can actually support us to live and cook the way we really want to. Want more? Come be part of our community and help support the continued work of the podcast! Our podcast is sponsored by our patrons and listeners who are also supported by the extra content that we share (think exclusive podcasts, live chats, cook ups and recipes) over at our http://patreon.com/ancestralkitchenpodcast (Patreon community!) From $5 a month (or equivalent in your currency) you'll be helping us with the costs of recording, editing and putting this work out into the world. And you'll get to be part of our community on a deeper level. "We had a tiny kitchen with a two-burner hob and a tiny fridge...we only had cold water in a tank under the van...I adored my kitchen in that van and I still miss it" The Run Down: 0:00-17:00: Intro to Charlie and what she last ate Charlie's family trip - why and where The van and its tiny kitchen 17:00-30:00 How she got good ingredients despite the language and culture barriers Highlights of food "Bread was baked freshly every day, they made their own charcuterie and liquors and then had apples pressed to cider and then they would make vinegar from them; they had tray of wild sliced mushrooms drying in the sun...Not long ago that's how we were all living" What she brought home 30:00-45:00 How often she cooked and how did she do it in the tiny space Home made pizza! Fermenting in the van and disasters 45:00 onwards: What Charlie learnt in and out of the kitchen "Our travels changed our perspective on life" Charlie's advice for those who have a small space and want to eat well If you like us and use Apple Podcasts, we'd love it if you left a review! Here's how: Open the Apple Podcast app Find Ancestral Kitchen Podcast in your library (you can search for it) Scroll down to 'ratings and reviews' Click on 'write a review', choose how many wonderful stars you would like to give us (!), title your review and then, in the lower box type a review of up to 300 words. Thank you. We really appreciate you taking the time to support us! Resources: https://babybusadventures.com/ (Charlie's Blog, Baby Bus Adventures) https://babybusadventures.com/camping-on-a-slovenian-farm/ (This is the amazing experience Charlie had in Slovenia.) https://babybusadventures.com/favourite-french-markets/ (Charlie's favourite French markets) https://www.agriturismoilrigo.com/en/home (The Italian Agriturismo where Charlie had the delicious rabbit meal) https://thenaturalweddingcompany.co.uk/ (Charlie's business, The Natural Wedding Company) (there's so much inspiration for eco-friendly weddings on the site) If you would like to be added to the WAPF UK parents facebook group that we mentioned, please contact Charlie via her Baby Bus social media and she'll sort it for you! "I really miss the limitations that were put on us by living in a van" Thank you for listening - we'd love to continue the conversation. Come find us on Instagram: Andrea is at http://instagram.com/farmandhearth (Farm
In today's episode of Empire, Jason and Santi are joined by the founders of Scroll - Sandy Peng, Ye Zhang and Haichen Shen - to discuss how ZK tech will scale Ethereum. Scroll is a general-purpose zkEVM rollup that combines Ethereum's security with drastically reduced fees and low latency. We start the conversation with a deep dive into zero-knowledge tech, the power of validity proofs and the different L2 scaling techniques. The team then explains Scroll's advantage, the difficulty of building a general-purpose L2 and why Scroll's “EVM equivalence” is a massive breakthrough for Ethereum developers. Scroll has been flying under the radar, but they won't be for long. Don't miss this conversation on the most sci-fi tech in crypto. - - Follow Scroll: https://twitter.com/Scroll_ZKP Follow Sandy: https://twitter.com/SandyPeng1 Follow Ye: https://twitter.com/yezhang1998 Follow Haichen: https://twitter.com/shenhaichen Follow Jason: https://twitter.com/JasonYanowitz Follow Santi: https://twitter.com/santiagoroel Subscribe To Our YouTube Channel: https://tinyurl.com/4fdhhb2j Subscribe on Apple Podcasts: https://tinyurl.com/mv4frfv7 Subscribe on Spotify: https://tinyurl.com/wbaypprw -- ParaSwap: If you want to make a swap at the best price across the DeFi market, check out paraswap.io. ParaSwap's state-of-the-art algorithm beats the market price across all major DEXs and brings you the most optimized swaps with the best prices and lowest slippage. -- Referenced in the show: Layer-2 for beginners https://gourmetcrypto.substack.com/p/layer-2-for-beginners?s=r Optimistic vs ZK Rollups https://blog.matter-labs.io/optimistic-vs-zk-rollup-deep-dive-ea141e71e075 -- (00:00) Intro (05:00) Scroll, a zkEVM Rollup (05:26) Why Is zk Tech Interesting? (07:58) Optimistic vs ZK rollups (10:26) The Evolution of ZK Tech (13:27) zkSync and Starkware (20:26) Where Is Scroll Today? (22:09) The Scroll Team (24:16) Moats In An Open-Source Industry (26:42) General-Purpose vs App-Specific Rollup (28:44) Paraswap Ad (29:44) Creating The Best Developer Experience (32:12) Working With The Ethereum Foundation (36:02) What Scroll Will Enable for Web3 (41:22) China and Web3 (46:17) Building and Investing (47:19) What's Next For Scroll? -- Disclaimer: Nothing said on Empire is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Santiago, Jason, and our guests may hold positions in the companies, funds, or projects discussed.
Sal Nicosia is a content creator, host, and on-air talent. He's the founder, turned co-host of Bananaland Podcast; a staple of South Jersey culture spawned from the wild experiences of pumping gas at Wawa, and transitioned to a conversational show covering topics like pork roll, dating and more. From his voice to his off-the-cuff opinions, Sal is positioned perfectly for the podcasting medium. After short-lived careers in radio and construction, Sal launched his podcast and personal brand and pivoted to content creation. He's now a full-time content creator for a diesel performance company in New Jersey. https://www.instagram.com/salnicosiajr/ (Follow Sal) https://open.spotify.com/show/0WGbJgESywUFybJcKqV0D5?si=f48d99b438314906 (Listen to Banaland ) Thank you for helping us become a top 10% podcast in the world! Previous Guests Include https://open.spotify.com/episode/4GLGc7gqDDDZdRqj4qlmwT?si=3306a470764646d5 (Rob Dyrdek), https://open.spotify.com/episode/2h9bHhMmQmL8WSSYDcj2mf?si=2a61889cb6244fe4 (Samad Savage), https://open.spotify.com/episode/2hudFx2Bh0no9aOpNVAfhL?si=b7f7c14b327f434b (Travis Chappell), https://open.spotify.com/episode/7r7aODbOtia2BjhG5GRcHh?si=ae47b9a90c21405d (Austin Belcak), https://open.spotify.com/episode/2ceJNa3MAyZlk8Lw3rsW1Q?si=e901236209e948f5 (Young Benny), https://open.spotify.com/episode/0qZVBnOGSUcAmt4EFphNcR?si=38763a2013084f6a (Adam Miller), https://open.spotify.com/episode/6lPiZinAXh3yDdSnLShDiA?si=74dc6a03560b4de9 (The Real Johnny Bravo), and more. Please Join Our Email List for Special Offers, Q+A's, Live Podcasts, and More - To Join, https://www.sullybop.com/ (Scroll to the Bottom of This Page) Links Below: _ Watch the Video Version on https://www.youtube.com/channel/UC5yW2ZNS4Iq7ff_EeKe3HkQ (YouTube) @sullybop on Instagram Search 'BOPCAST' on any platform! (Google Podcasts, Apple Podcasts, Spotify, YouTube) Visit https://www.sullybop.com/ (SullyBop.com) for more information. Big shouts to the folks who make this possible: Video - https://www.instagram.com/ferrarib98/ (@ferrarib98) Logo - https://www.instagram.com/ryannkelly20/ (@ryannkelly20) Producer - https://www.instagram.com/minishep13/ (@minishep13) Theme Song - https://www.instagram.com/jello.wav/ (@jello.wav)
Episode 101 - all notes from the show can be found at www.zippingaroundtheworld.com on the home page. Scroll to find Episode 101. Don't forget to subscribe to the show! Tell your friends and social media. Leave me a comment on my website under the comments tab if you have ever used any of my travel tips or locations.
Tribe Sober - Your guide to alcohol-free living! After running Tribe Sober for 6 years and helping hundreds of people to ditch the drink and embrace alcohol-free living I've learned a lot. My biggest insight has been that sharing our stories around our problems with alcohol is the most powerful way we can help others - that's why the heart of this podcast is recovery stories. Today I celebrate seven years of sobriety so I'm sharing my story - how I quit drinking and started Tribe Sober In this Episode How I got hooked on the booze - and nearly drowned - and carried on drinking How I got breast cancer - and carried on drinking How I kept trying (and failing) to "moderate" How a "walking, talking blackout" made me (finally) decide to ditch the drink How I went to AA and why it didn't work for me How I finally found "my people" at a one day workshop in London and managed to stop drinking How I stayed sober - and decided to use my training experience to design a workshop to help others How the workshop participants wanted to stay connected and Tribe Sober membership was born How I marked my first Soberversary by writing a "Goodbye to Alcohol" Letter How I'm celebrating my seventh Soberversary by developing an online course which will be available in July 2022 More Info Subscription membership – you can join up HERE. 20% ANNUAL MEMBERSHIP DISCOUNT CODE ANN052022 – valid during May 2022 To access our website, click HERE. If you would like a free copy of our “Annual Tracker” or our e-book 66 Days to Sobriety, please email firstname.lastname@example.org. If you would like to come to our Saturday afternoon Zoom Cafe as a guest and meet our community, just email email@example.com. Episode Sponsor This episode is sponsored by the Tribe Sober Membership Program. If you want to change your relationship with alcohol then sign up today Read more about our program and subscribe HERE Book a Discovery Call with me to find out if our membership would help you Help us to Spread the Word! We made this podcast so that we can reach more people who need our help. Please subscribe and share. If you enjoyed the podcast, then please leave us a 5-star review on Apple podcasts. Take a screenshot of your review, and DM it to Tribe Sober's Instagram page – see PS below for instructions. We'll send you something special to say thank you! We release a podcast episode every Saturday morning. You can follow Tribe Sober on Facebook, Twitter, TikTok and Instagram. You can join our private Facebook group HERE. PS: How to Leave a Rating/Review in Apple Podcasts (on an iOS Device) Open the Podcasts app. EASY. Choose “Search” from the bottom row of icons and enter the name of the show (e.g. Recover Like a Mother) into the search field. Select the show under Shows (not under Episodes). Scroll down past the first few episodes until you see Ratings & Reviews. Click Write a Review underneath the displayed reviews from other listeners. You'll then have the option to rate the show on a 5-star scale and write a review (you can rate without writing too but it's always good to read your experience).
Awesome teachers connect with their students. KeKe Powell teaches second grade and has lots of ideas for ending the year and also just connecting with kids. She also shares some of her story of deciding to share what she does with a wider audience as she is becoming an education influencer. If you're considering if you want to share or if you just want great teaching ideas, this is a great listen for you. Scroll down for the show notes and transcript. Notes and Transcript: https://www.coolcatteacher.com/e782 Sponsor: Advancement Courses Last summer I took my professional development with Advancement Courses and I am so glad that I did! On my blog, I recently shared 10 Ways to Rejuvenate and Learn This Summer. All of the course ideas come from the advancement courses catalog to go to https://www.coolcatteacher.com/top10 Learn about some courses you might want to take and some things that you need to do this summer. Your current needs should impact your professional development. Advancement Courses makes it so easy to complete your PD with courses that are online and self-paced so you can take them anywhere any time with up to six months to complete. And right now you can use the code COOL15 to get 15% off your course today. So go to www.coolcatteacher.com/top10 and begin deciding what you want to learn this summer. Keke Powell - Bio as Submitted Just a teacher learning and spreading my aloha with others! I relocated from Hawaii to the great state of Texas! I enjoy learning new things and exploring the outdoors. Blog = www.mspowellteaches.com Twitter = @mspowellteaches Instagram = @mspowellteaches TikTok = @mspowellteaches_ Linked in - https://www.linkedin.com/in/mspowellteaches/ I have created my platform to showcase ways I implement new things in my classroom. I have learned so many new things from other educators and I enjoy to continue to pay it forward! As educators, we are all doing great things inside our classroom and I believe we should highlight each others success! Disclosure of Material Connection: This is a “sponsored podcast episode.” The company who sponsored it compensated me via cash payment, gift, or something else of value to include a reference to their product. Regardless, I only recommend products or services I believe will be good for my readers and are from companies I can recommend. I am disclosing this in accordance with the Federal Trade Commission's 16 CFR, Part 255: “Guides Concerning the Use of Endorsements and Testimonials in Advertising."
The 5D Academy with Zarathustra explores universal wisdom to foster total freedom from suffering in all areas of your life; health, wealth, love, and self. Each Academy podcast contains valuable insights and takeaways to become the best version of yourself and create an authentic, fulfilling life. Zarathustra transmits 5th Dimensional Quantum frequencies in each episode with transformational tools while discussing different topics to help you maintain this new frequency in your daily life. Zarathustra has created a practical system of transmitting the truth to his audience allowing transformation and freedom from suffering. Spiritual development requires an open heart. It is virtually impossible for a seeker to advance to higher consciousness if they don't love themselves. The belief system which has been ingrained in our cellular memory from childhood that we are not good enough results in a conditioned mind. The conditioned mind holds the false belief that there is something missing in our lives, that we are incomplete, that we need to gain something in order to become happy and whole, which is not true. After a life time of searching, Zarathustra has blended a practical system of Eastern and Western methods and techniques to help the Academy members to free themselves from anxiety, negative thoughts, lack of self-love and self-acceptance and destructive emotional patterns through a systematic way to raise your vibration to 5D Vibrational Frequency, which enables you to live a vibrant life of freedom and happiness. The Key Elements To Freedom: Zarathustra recognizes continuity and consistency are the key elements to freedom. In order to help you achieve your spiritual goals, it's best to have a highly effective spiritual practice, free of dogmas, false beliefs and superstition that helps you raise your vibration to 5D Vibrational Frequency as well as the ability to maintain this newly found higher level of consciousness. This translates to a life filled with inner peace, self-love and happiness which is the goal of every spiritual seeker. New knowledge and benefits are gained with each replay. Scroll down for a record of all 5D Academy podcasts and for more information about Zarathustra's 5th Dimensional Academy of Higher Consciousness, Upcoming Events, Workshops or 5th Dimensional Quantum Healing & Awareness Training Programs, please visit: www.Zarathustra.TV WARNING: The 5D Academy transformational process is highly effective and very intense. You may find it severely challenging as old patterns shift. Working with Zarathustra requires absolute ownership and personal accountability. If you are mentally unstable, weak, tend to blame others, and/or are unwilling/unable to take personal responsibility please do NOT proceed. Zarathustra is not a doctor and makes no medical claims. Nothing Zarathustra or any agents/employees of 5th Dimensional Quantum Awareness communicates should be construed as medical or psychological advice of any kind. Please see a health professional for all medical assessments & treatments. By viewing this statement and using any products, services or information contained herein, you agree to our Disclaimer and agree to indemnify and hold harmless Zarathustra, 5th Dimensional Quantum Healing & Awareness and any employees/agents of the Company of any liabilities. Website: www.zarathustra.tv/Facebook: www.facebook.com/zarathustra5d/Instagram: www.instagram.com/zarathustra5d/YouTube: www.youtube.com/zarathustra5dTwitter: www.twitter.com/Zarathustra5d
In this episode of the iCantCU Podcast, I talk about Global Accessibility Awareness Day #GAAD2022. It started off with, you guessed it, an accessibility issue with a website for me just after midnight. And that wasn't the only one that day. I also share a story about our monthly Keystone Chapter meeting that included a field trip to a venue across town for an upcoming fundraiser. There's also a cornea transplant post op update. Show notes at https://www.iCantCU.com/180 Global Accessibility Awareness Day There is nothing more frustrating than going to a website or opening an app only to need help from someone sighted to use it. Learn more about the day and what digital accessibility is at https://accessibility.day/. You can also see previous year's events at https://accessibility.day/past-events/#events-list. Support The iCantCU Podcast Some people have asked how they can support the podcast since I don't do Patreon. The easiest way is to use my link when you want to make a purchase at Amazon. I participate in the Amazon Associate Program and earn a small commission on qualifying purchases. It doesn't cost you anything extra on the items you purchase. Here's the link: https://www.iCantCU.com/amazon. This will take you to Amazon's homepage where you can search and buy what you want. White Canes Connect Podcast Listen to another podcast that I cohost and produce called White Canes Connect. In episode 034, we talk with Angelina from the Angelina Sings YouTube Channel at https://www.youtube.com/channel/UCHwQzjXhXwwGF0Yn3RBM_-Q. She tells us how she started singing when she was very young (she's only 16 now) and how she taught herself to play the piano. She gives out some tips on how you can do it, too. Apple Podcasts https://podcasts.apple.com/us/podcast/white-canes-connect/id1592248709 Spotify https://open.spotify.com/show/1YDQSJqpoteGb1UMPwRSuI IHeartRadio https://www.iheart.com/podcast/263-white-canes-connect-89603482/ Amazon Music https://music.amazon.com/podcasts/7dd1600d-05fa-48f3-8a8e-456e30e690bc/white-canes-connect My Podcast Gear Here is all my new gear and links to it on Amazon. I participate in the Amazon Associates Program and earn a commission on qualifying purchases. Zoom Podtrak P4: https://amzn.to/33Ymjkt Zoom ZDM Mic & Headphone Pack: https://amzn.to/33vLn2s Gator Frameworks Desk Mounted Boom Arm: https://amzn.to/3AjJuBK Shure SM58 S Mic: https://amzn.to/3JOzofg Senheiser Headset (1st 162 episodes): https://amzn.to/3fM0Hu0 Support Keystone Chapter Please make a donation to the Keystone Chapter of the National Federation Of The Blind Of Pennsylvania by going to http://www.SupportKeystoneChapter.org.. Scroll down to the text field and enter the amount you'd like to donate. Payments are handled by PayPal, but you don't need a PayPal account. You can make a donation with any credit or debit card. Thank you so much! I really appreciate it. Follow the iCantCU Podcast so you don't miss an episode! Apple Podcasts | Spotify | Amazon | Google | IHeartRadio Reach Out On Social Media Twitter | Instagram | Facebook | LinkedIn Get In Touch If you've got questions, comments, or show ideas, I want to hear from you! Call (646) 926-6350 and leave a message. Include your name and town and let me know if it is okay to use your voice on an upcoming episode. You can also email the show at iCantCUPodcast@gmail.com
Sometimes the Universe takes matters into it's own hands (especially when you've been ignoring its whispers and nudges for years). When my Instagram got hacked and I "lost" everything I had built in an instant? I mourned the loss of my old identity and community for weeks...wondering if I had the energy to pick up and pour into re-creating myself again from the ground up. But what I came to realize with time was that it was never about "starting over"...it was always about a coming home to the truth that what I'm creating is never going to be static, done, safe, or secure. That there is an infinite wave cycling through its phases in my life and that I need to trust in each phase of that process - not just when things are peaceful. This episode invites you to look at your own gripping patterns...your own universal whispers...and the waves that are building around you in a new welcoming way.----------
Scroll is a Digital Marketing company located in Kaysville. The company is owned by Kaysville residents: Dan Page and Shane Hickenlooper. Scroll was created to provide full-service, in-house digital marketing services for companies large and small with the goal of increasing online marketing and sales. In addition to being creative entrepreneurs, Dan and Shane are exceptional business managers. Their agility and ability to quickly pivot allowed their company to not only survive but thrive during the economic shutdown of a worldwide pandemic. Dan and Shane understand what it takes to build an influential, professional, strategic, digital marketing plan that allows companies to grow they did it for their company, and can do it for yours. www.joinscroll.com
When you started your agency, you probably had some end goals in mind. A lot of people dream about selling their agency, but the reality is that it's very difficult to sell a service-based business (and make a decent amount of money). So perhaps a better option is to focus on building an agency that is less dependent on you. i.e. a Self-Running Agency. Now, you know I'm a big fan of this approach since I have my book called The Self Running Agency, and I also have my membership group (The Self-Running Agency Implementation Group) and this is a strategy I help my clients deliver. So in today's podcast, I am delighted to be joined by someone who is doing just this, Simon Isaac, MD and Owner of Capsule Marketing. Time Stamp [01:33] Introduction to Simon Isaac and Capsule Marketing and why he wants to build a Self-Running Agency [02:22] Simon's journey to starting and growing a marketing agency [03:53] What were your hopes and plans in the first couple of years of running your agency [05:16] Who were your first hires when you started hiring staff? [07:06] Why did you decide you wanted to start removing yourself from the day-to-day running of Capsule? [08:43] Simon's passions and interests outside of Capsule (and why he wanted more time to pursue these) [10:15] The typical entrepreneur: an ideas person but not a completer/finisher [10:40] Simon outlines the key steps taken so far to start building a Self-Running Agency and not work 5-days a week in the agency. The importance of hiring a great number 2 and an empowered team [13:10] “It's lonely at the top” - The importance of having external advisers (that you listen to!) who can act as our board and provide expert objective advice [15:17] How and why did you put together a Senior Leadership Team [16:00] Creating opportunities for growth for all the team [17:22] Simon's experience of moving from a corporate world to a creative world - and the many lessons to take from his past corporate life. [18:20] Creativity is not stifled by implementing systems [18:40] Simon's future plans and how he is ensuring they are delivered [20:30] The importance of letting go and trusting others [20:57] What advice do you have for other agency owners who are still completely entrenched in delivering client work? [22:10] What if you did delegate and it all went wrong? [24:30] Don't recruit ‘in your like' but rather hire people who are better than you [25:30] If you could go back in time and give your younger self one piece of advice, what would it be? Quotations “It's so important to regularly stop working in your business, take a breath, get a high-level view to know what your need to focus on before you take the pause button off” - Rob Da Costa “Trust your people, invest in them and have high expectations of them” - Simon Isaac “Surround yourself with people who are better than you and don't feel threatened by them” - Simon Isaac Rate, Review, & Subscribe on Apple Podcasts “I enjoy listening to The Agency Accelerator Podcast. I always learn something from every episode.” If that sounds like you, please consider rating and reviewing my show! This helps me support more people — just like you — move towards a Self-Running Agency. Scroll to the bottom, tap to rate with five stars, and select “Write a Review.” Then be sure to let me know what you loved most about the episode! Also, if you haven't done so already, subscribe to the podcast. I'm adding a bunch of bonus episodes to the feed and, if you're not subscribed, there's a good chance you'll miss out. Subscribe now! Useful links mentioned in this episode: Find out more about Simon: Simonisaac.co.ukThe Self-Running Agency BookThe Self-Running Agency Implementation Group
In 622 B.C.E., the High Priest Hilkiah reported a great discovery – the original scroll of the Torah of Moses! The details of that discovery are recorded in the Hebrew Bible (2 Kings 22-23 and 2 Chronicles 34-35). A careful examination of these texts of the discovered scroll and the subsequent reform of King Josiah […]
Are you preparing for bariatric surgery or maybe you just had it recently. What questions are on your mind that you wished you had asked your surgeon? Bariatric surgeon Dr. Andre Teixeira is in the house answering your questions on this episode of Bariatric Surgery Success.Visit Procarenow.com for all of your vitamin, calcium and protein needs. Use Code: Susan10 to save 10%Guest: Dr. Andre TeixeiraInstagram: @bariatricdrteixeiraFacebook: https://www.facebook.com/bariatricdrteixeiraOrlando HealthBariatric and Laparoscopy Center89 Copeland Drive, 1st FloorOrlando, Fl 32806321-843-8900Dr. Andre Teixeira is a board-certified bariatric physician for Orlando Health Physicians Bariatric and Laparoscopy Center in Orlando Florida. And he also works with bariatric dietitian Gayle Smith whom you know and joins me regularly on the podcast. In fact I recently read a journal article in Obesity Surgery written by Dr. Teixeira, Gayle and two other professionals on low calorie sweeteners. Some of the questions he answers include:When you see a potential surgery patient for the first time, what are the most common questions you are asked?Will I stop losing weight at a certain point and gain back?I feel like I am a slow loser. How much weight is average loss post surgery?What is the % success (keeping the lost weight) after a sleeve on long term (5-10 years)?How much weight will I lose?I am 2 years post op and I have not lost as much weight as I would like, not at 100 pounds yet, no gains though. Will this change?Please write a review on Apple Podcasts"I love Dr. Susan and Bariatric Surgery Success." If this sounds like you, would you please rate and review my podcast? Click here. Then click on "Listen to Apple Podcasts" at the top. Scroll down to where you see Ratings & Reviews and tap on "Write a Review". Yes, I'd love a 5 star review! LOL Be sure and let me know what you love most about the podcast. Thank you for your time! If you haven't followed the podcast, be sure to Follow/Subscribe now so you never miss an episode.
Being Known Podcast normally ends our season with a wrap up episode highlighting each episode with one more nugget of wisdom. This season we mixed things up a bit and asked our listeners and followers what they wanted to know more about. We received over 40 questions seeking additional wisdom on sexual trauma, generational trauma, trauma and the church and more. A few of the questions asked include: How does trauma play out in our relationship with God? And how does this affect our ability to attune to God? Can trauma cause a type of amnesia where we forget past events? And why/how does this happen? If I already have grown children, is it too late to heal my trauma and not pass my trauma onto my kids? In Curt's own words, “I thoroughly enjoyed this opportunity to end the season. It allowed us to be live action and real time. It offered us a glimpse of what people are learning and what they desire to learn more about.” Sign up to access the Being Known Podcast applications, the weekly exercises that connect what you are learning to your life in a practical way. Scroll to the bottom of the page to sign up (not the pop-up). As always, we invite you to stay connected with us via social media and YouTube: Instagram Facebook Twitter YouTube (where we post the unedited videos of each episode AND the post show conversations.) Please subscribe to the podcast so you never miss an episode and we always welcome your reviews on Apple Podcasts.
The Lord's Prayer of the New Testament is modeled after the Prayer of John the Baptist. “Master, teach us to pray, just as John taught his disciples.” (Gospel of Luke) In light of this, today we begin by examining the Lord's Prayer from various translations including some that are rather mindful of the Aramaic roots of the Jesus Movement. We also consult with the Gospel of the Nazoreans. Shared as well during this program is: 1) a Prayer of John found in a Syriac Aramaic manuscript; 2) a vegetarian saying attributed to the Prophet John present in the Slavonic Book of Josephus; 3) another vegetarian saying of John located in the Scroll of John the Baptizer (Drasa d-Yahya); 4) along with several passages from the famous Mandaean Gnostic scholar Ethel Stefana Drower commenting on the vegetarianism of the original John the Baptist sect of the Trans-Jordan known as the Nasoraeans (Nazoreans). And then 5) the main feature of today's Spiritual Awakening Radio podcast: readings from the Hidden Words of John, a collection of wisdom sayings found in the Great Treasure, some ancient manuscripts written in the Mandaic dialect of the Aramaic language. This 'proverbs' or 'sayings' type format of "The Instructions of John the Baptist" reminds me very much of another book from antiquity, and it also happens to be attributed to John's most famous disciple Yeshua: The Gospel of Thomas, "hidden words that the living Jesus spoke." Readers of the New Testament and extra-canonical scriptures of the various early Jewish, Christian and Gnostic sects typically aren't used to seeing many actual direct quotes from John, and yet there are many sayings to be found if one knows where to look. Today's podcast is dedicated to the teachings of the Prophet John (Yuhana) the Baptist, a mysterious "voice crying out in the wilderness." All for the Love of Wisdom, Radio, and Podcasts, James Bean Spiritual Awakening Radio https://www.SpiritualAwakeningRadio.com
Kid News This Week: Russia furious at NATO's Nordic expansion while Turkey says no-no, UK's post-drones take off, possible microchip in Aussie footballs, jail for dumbest thieves
Most coaches will never reach a level of true confidence in how they show up for, lead and communicate with their clients.Why?Because when progress sucks…clients get frustrated…and we feel like we should be doing more.We fall back into doing the only thing we know.We research hot new trends that might work better…try a different strategy…tweak their plan…and hold them MORE accountable.Thing is, all that stuff is good and all.But chances are the last thing you need is another fancy nutritional approach to try with a tricky client.Listen.I know it feels easier to think you're missing something in your program that would make everything “click” for them.Or that they just need to come back to their deeper “why” to feel all filled up with the motivation they need to consistently chase after what you see as possible for them.But that's all just smoke in mirrors.>>> What you actually need is:A new way to communicate with that client about the real reason they are consistently stuck spiraling, making excuses and fighting for their limitations…the skills to open a space where breakthrough becomes possible simply because a new level of trust…buy-in…and awareness joins you in the room…to feel capable of holding that space for your client to move through feeling triggered, emotional and reactive (without getting shaky, yourself) so that true change can take place.^^ THIS ^^ is what COACHING WITH CONVICTION™ is all about. Listen to the Q & A Now
This week we look at the consequences of years of “chumming for monsters,” as monsters of all varieties rise to the taste of blood. We also take a more indepth look at Rob Pincus' Intuitive Defensive Shooting concepts. MichaelBane.TV - On the Radio episode # 120. Scroll down for reference links on topics discussed in this episode. Disclaimer: The statements and opinions expressed here are our own and may not represent those of the companies we represent or any entities affiliated to it. Host: Michael Bane Producer: Flying Dragon Ltd. More information and reference links: THE BEST DEFENSE is available on http://myoutdoortv.com MB “Chumming for Monsters” podcast 3.23.2021 MB “Why We Chum For Monsters” blogpost 8.26.2015 “Thresholds of Violence”/Malcolm Gladwell I.C.E. Training Intuitive Defensive Shooting one day class Active Shooter Response/Rob Pincus, USCCA Personal Defense Network U.S. Concealed Carry Association USCCA Defensive Shooting Fundamentals digital training course DEFENSIVE SHOOTING FUNDAMENTALS Book 1/Pob Pincus USCCA The Music of Ben Winwood The Music of Ben Noble
When my travel digestion woes didn't resolve, I started an elimination diet to see what could be at the root of my distress. I've got some good clues, and I'll share a few things I'm eliminating and how I'm feeling. Does chasing happiness work? We'll revisit an episode from two years back that has great relevance right now, and we'll also touch on fermented foods, which have so many potential benefits, but which I'm avoiding for the moment. Lots of steps' worth today! LET'S TALK THE WALK! Wellness While Walking Facebook page Wellness While Walking on Instagram Wellness While Walking on Twitter Wellness While Walking website for show notes and other information Coach Carolyn on Clubhouse: @stepstowellness firstname.lastname@example.org RESOURCES AND SOURCES (some links may be affiliate links) My Elimination Diet - New Segment! Unfunc Your Gut: A Functional Medicine Guide, Dr. Peter Kozlowski Doc Koz was on Episodes 73 and 74, and then we spoke about Elimination Diets more in Episode 75 – all are linked here. There is a lot of detailed information about Elimination Diets in his book -- highly recommend! Ep. 73: Gut Health is Crucial for Overall Health with Doc Koz Ep. 74: Doc Koz Part 2: The Gut is the Heart of the Matter Ep. 75: Elimination Diets, My Stomach Acid Volcano + We All Could Use a Health Coach Kombucha, Kimchi and Yogurt: How Fermented Foods Could Be Harmful to Your Health, theconversation.com What You Should Know About Sugar Alcohols, clevelandclinic.org Positivity-Replay States of Positivity Include: joy, gratitude, serenity, interest, hope, pride, amusement, inspiration, awe, love Positivity, Barbara Fredrickson, PhD Prioritizing Positivity Optimizes Positive Emotions and Life Satisfaction, researchgate.net Monterey Bay Aquarium – live cams (check them all out! These 6 Simple Habits Can Help Calm Your Coronavirus Anxieties, fastcompany.com Long-Term Mental Health PTSD Effects of Covid-19 Pandemic Explained, cnbc.com Five Ways to Conquer Your Covid-19 Fears, wapo.com Barbara Fredrickson: Positive Emotions Transform Us - video FACE COVID - video A Course Correction for Positive Psychology, greatergood.berkeley.edu Reflections on Positive Emotions and Upward Spirals, Barbara Erickson, sagepub.com Positive Emotions: A Guide to Increase the Your Quality of Life, blog.cognifit.com Are You Getting Enough Positivity in Your Diet? greatergood.berkeley.eud Fermented Foods-Replay Autoimmune Gut Repair Diet, drknews.com Could Fermented Foods Boost Your Health? webmd.com Health Benefits of Kimchi (Korean fermented vegetables) as a Probiotic Food, ncbi.nlm.nih.gov/pubmed Fermented Foods for Better Gut Health, health.harvard.edu An Introduction to Probiotics, mayoclinichealthsystem.org Fermented Foods: Definitions and Characteristics, Impact on the Gut Microbiota and Effects on Gastrointestinal Health and Disease, ncbi.nlm.nih.gov/pubmed Why Fermented Foods Don't Work for Everyone, bulletproof.com Why Your Gut Health is More Important Than You Probably Think, humanlongevityfilm.com Why You Shouldn't Count On Fermented Foods Alone for Better Gut Health, wellandgood.com My Daughter's Favorite Kombucha! HOW TO SHARE WELLNESS WHILE WALKING Wellness While Walking on Apple Wellness While Walking on Spotify Link for any podcast app: pod.link/walking Wellness While Walking website Or screenshot a favorite episode playing on your phone and share to social media or to a friend via text or email! Thanks for sharing! : ) HOW TO RATE AND REVIEW WELLNESS WHILE WALKING How to Leave a Review on Apple Podcasts on Your iOS Device Open Apple Podcast App. Go to the icons at the bottom of the screen and choose “search” Search for “Wellness While Walking” Click on the SHOW, not the episode. Scroll all the way down to “Ratings and Reviews” Click on “Write a Review” Then you will be able to rate the show on a five star scale and write a written review! Thank you! How to Leave a Review on Apple Podcasts on a Computer Visit Wellness While Walking page on Apple Podcasts in your web browser Click on “Listen on Apple Podcasts” This will open Apple Podcasts and should bring you to the show, not a particular episode Scroll down until you see “Rating and Reviews” You may need to click on “See all” all the way to the right, near the Ratings and Review Section On the right side, you should see 5 empty stars – click on the one farthest to the right if you want to give the show 5 stars To leave a verbal review, please then head left and click on “Write a Review” Thank you! How to Leave a Review on Spotify App on Your Phone Open the Spotifyapp on your device. Tap the Searchtab, then type Wellness While Walking on the search bar; this will lead you to the podcast's show page. If you are on a specific episode, just tap on the podcast's thumbnail and title to be redirected back to the show page. Tap the rating immediately underneath the podcast's description. Alternatively, tap the More (…)icon, then choose Rate show. Drag your finger or tap on one of the five stars to leave a rating. Thank you! The following apps might also allow you to rate and review the show. As of March 2022, there's no way to rate or review a show on Google Podcasts. Castbox Podcast Addict Podchaser Podbean Overcast (if you star certain episodes, or every one, that will help others find the show) DISCLAIMER Neither I nor many of my podcast guests are doctors or healthcare professionals of any kind, and nothing on this podcast or associated content should be considered medical advice. The information provided by Wellness While Walking Podcast and associated material, by Whole Life Workshop and by Bermuda Road Wellness LLC is for informational and entertainment purposes only. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment, and before undertaking a new health care regimen, including walking. Thanks for listening to Wellness While Walking, a walking podcast and a "best podcast for walking"!